GGrantIndex
Sort

8,912 grants matching sars cov 2

The Role of COVID-19 Endothelial Cell Dysfunction and Hypercoagulability in the Development of Post-ICU Cognitive Impairment and Dementia

$237,750
Sophia Wang · Indiana University Indianapolis · R21 · FY2022 · AG

Pediatric COVID-19 Dashboard and Clinical Phenotypes

$237,623
Tellen Bennett · University Of Colorado Denver · R01 · FY2023 · HD

Evaluating Clinical and Immunological Consequences of SARS-CoV-2 Vaccination in Rheumatic Disease

$237,514
Robyn Therese Domsic · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AR

Analysis Resource Core

$237,501
Scott L. Zeger · Johns Hopkins University · U54 · FY2022 · CA

Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics

$237,381
Kathryn A. Cunningham · University Of Texas Med Br Galveston · UG3 · FY2020 · DA

A Helminth-Derived Immune Potentiator for Biodefense

$237,000
New York Blood Center · R21 · FY2005 · AI

mRNA COVID-19 Vaccines Delivered with Plant Virus/Polymer Devices

$237,000
Nicole Franziska Steinmetz · University Of California, San Diego · R21 · FY2021 · AI

Mechanistic & Crystallographic Studies of SARS Proteases

$236,986
Andrew D Mesecar · University Of Illinois At Chicago · P01 · FY2006 · AI

Impact of Alcohol Misuse on Cognitive and Respiratory Outcomes in COVID-19-associated Acute Respiratory Failure

$236,921
Ellen L Burnham · University Of Colorado Denver · R01 · FY2023 · AA

Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants

$236,919
Sagar D Khare · Rutgers, The State Univ Of N.J. · R21 · FY2023 · AI

Discovery of Novel Anti-inflammatory, Non-immunosuppressive Molecules forMitigation of Cytokine Storm in COVID-19 Patients

$236,387
Mehran F Moghaddam · Orox Biosciences, Inc. · R43 · FY2022 · HL

Intracellular functions and mechanisms of alphavirus ion channel 6K

$236,286
Joyce Jose · Pennsylvania State University, The · R21 · FY2023 · AI

Impact of SARS-Cov-2 on a Rat Model Cerebral Amyloid Angiopathy

$236,250
William E. Van Nostrand · University Of Rhode Island · R21 · FY2025 · AG

E-PROOF: E-intervention for Protein Intake and Resistance Training to Optimize Function

$236,250
Jessica L. Krok-Schoen · Ohio State University · R21 · FY2023 · AG

Therapy for long-COVID in a preclinical model

$236,250
Daniel Kaufman · University Of California Los Angeles · R21 · FY2024 · AI

Regulation of Cell Death and Inflammation by ISG15 during SARS-CoV2 Infection

$236,250
Deborah J Lenschow · Washington University · R21 · FY2022 · AI

Obesity and COVID-19: Role of Adipose Tissue

$236,175
Tracey McLaughlin · Stanford University · R21 · FY2021 · AI

Characterization of host immune responses to SARS-CoV-2

$236,110
Luigi Notarangelo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Covalent inhibitors of host cell entry by SARS-CoV-2 for treatment of COVID-19

$236,100
Matthew S Bogyo · Stanford University · R21 · FY2023 · AI

Determining SARS-CoV host gene requirements by mutagenesis and RNA interface

$236,097
Robert J Hogan · University Of Georgia · R21 · FY2007 · AI

Rapid detection of infectious viral particles by cluster induced exhaustive reaction

$235,887
Jun Wang · State University New York Stony Brook · R21 · FY2022 · AI

Qungasvik (Toolbox): Prevention of Alcohol/Suicide Risk in Alaska Native Youth

$235,846
Stacy M. Rasmus · University Of Alaska Fairbanks · R01 · FY2020 · AA

A decision tool to inform the optimal use of non-pharmaceutical interventions during the COVID-19 pandemic

$235,692
Reza Yaesoubi · Yale University · R21 · FY2024 · AI

Live-cell imaging of SARS-CoV-2 replication organelle formation and RNA synthesis

$235,550
Zandrea Ambrose · University Of Pittsburgh At Pittsburgh · R21 · FY2024 · AI

ACE2-independent alternative receptors for SARS-CoV-2 at the oral mucosa

$235,500
Theresa L Chang · Rutgers Biomedical And Health Sciences · R21 · FY2024 · DE